The expert evaluation results of the adjustment of the innovative drug catalog for health insurance and commercial insurance in 2025 have been released. A company on-site communication meeting is scheduled to be held in Beijing in the near future.

On September 20th, the National Healthcare Security Administration website announced that the agency recently released a notice on the interim results of the expert review stage of the declaration of drugs for the adjustment of the National Basic Medical Insurance Catalog and Commercial Insurance Innovative Drug Catalog by 2025 through formal review. According to the work plan for adjusting the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogs, as well as the Commercial Health Insurance Innovative Drug Catalog by 2025, the National Healthcare Security Administration organized experts to review the drugs declared for the adjustment of the National Basic Medical Insurance Catalog and Commercial Insurance Innovative Drug Catalog by 2025 through formal review. The review has been completed, and relevant enterprises can check the review results themselves. For drugs outside the catalog that were reviewed as "to be negotiated for inclusion", "to be competitively added", or "to be price negotiated", it means that the drugs have been included in the scope of negotiation/competitive bidding/price negotiation for the 2025 National Basic Medical Insurance Catalog and Commercial Insurance Innovative Drug Catalog, and have qualified for negotiation/competitive bidding/price negotiation, but does not mean that they have been included in the National Basic Medical Insurance Catalog or Commercial Insurance Innovative Drug Catalog. The National Healthcare Security Administration plans to hold an on-site communication meeting for enterprises eligible for negotiation/competitive bidding/price negotiation in Beijing in the near future.